scholarly journals CLINICAL AND LABORATORY FEATURES OF PATIENTS WITH COMORBID ASSOCIATION OF BRONCHIAL ASTHMA AND OBESITY

2021 ◽  
Vol 17 (77) ◽  
pp. 82
Author(s):  
M. M. Kochuieva ◽  
V. G. Psarova ◽  
H. A. Tymchenko ◽  
O. S. Komissarova ◽  
A. V. Marchenko ◽  
...  
2015 ◽  
Vol 12 (5) ◽  
pp. 9-16
Author(s):  
I V Demko ◽  
E A Sobko ◽  
I A Soloveva ◽  
A Yu Kraposhina ◽  
O P Ishenko ◽  
...  

Background. To study the clinical and functional features in interrelationship between the level of proinflammatory and antiinflammatory cytokines in young patients with bronchial asthma and alimentary obesity for optimization of therapy. Methods. 133 persons were examined: 93 patients with bronchial asthma were divided into 2 groups depending on body weight index (BWI): the 1st group included patients with bronchial asthma with BWI less than 25 kg/m2, the 2nd group included patients with bronchial asthma with BWI 30 kg/m2 and more. The group of control included 40 almost healthy persons. We studied external respiration function, cellular structure of the induced sputum, the level of TNFα, IL-2, IL-4, IL-6, IL-15, Creactive protein in blood. Results. The results of cytokines at patients with bronchial asthma depending on BWI out of an exacerbation of the disease within the last 2 months. We found the signs of more significant systemic inflammation in the group with obesity the increasing of the level of IL2, IL6, TNFa and Creactive protein in plasma was found. Conclusion. We found that there was more sever course of bronchial asthma in young patients with obesity, decreased external respiration functions, increased level of proinflammatory cytokines and proteins of acute phase in peripheral blood.


1950 ◽  
Vol 34 (6) ◽  
pp. 1829-1838 ◽  
Author(s):  
John J. Curry
Keyword(s):  

2019 ◽  
Vol 1 (7) ◽  
pp. 29-32 ◽  
Author(s):  
L. S. Kruglova ◽  
E. M. Gensler

Over the past decades, the first breakthrough milestone in the treatment of severe forms of atopic dermatitis (AD) has been targeted therapy aimed at inhibiting IL-4 and IL-13. This was made possible thanks to advances in the understanding of the pathogenesis of AD, the driver of which is the Th2-type immune response, which also underlies such manifestations of atopy as bronchial asthma, allergic rhinitis, and polynosis. In the case of the Th2-type immune response, cytokines IL-4 and IL-13 are secreted, which are the main promoters of the inflammatory response in AD. Inhibition of IL-4 and IL-13 leads to the prevention of inflammation and is an effective approach to therapy. The use of therapy aimed at inhibition of cytokines allows you to effectively cope with the manifestations of severe and moderately severe blood pressure.


Sign in / Sign up

Export Citation Format

Share Document